Brain PET metabolic abnormalities in patients with long-lasting macrophagic myofasciitis

[1]  A. Bachoud-Lévi,et al.  FDG-PET/CT Brain Findings in a Patient With Macrophagic Myofasciitis , 2016, Nuclear Medicine and Molecular Imaging.

[2]  A. Bachoud-Lévi,et al.  Neuropsychological Correlates of Brain Perfusion SPECT in Patients with Macrophagic Myofasciitis , 2015, PloS one.

[3]  M. Rigolet,et al.  Clinical Features in Patients with Long-Lasting Macrophagic Myofasciitis , 2014, Front. Neurol..

[4]  O. Tillement,et al.  Slow CCL2-dependent translocation of biopersistent particles from muscle to brain , 2013, BMC Medicine.

[5]  P. Brugières,et al.  Long-term follow-up of cognitive dysfunction in patients with aluminum hydroxide-induced macrophagic myofasciitis (MMF). , 2011, Journal of inorganic biochemistry.

[6]  P. Brugières,et al.  Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction. , 2009, Journal of inorganic biochemistry.

[7]  E. Guedj,et al.  Clinical Correlate of Brain SPECT Perfusion Abnormalities in Fibromyalgia , 2008, Journal of Nuclear Medicine.

[8]  J. Bleiberg,et al.  The effects of multidisciplinary therapy on positron emission tomography of the brain in fibromyalgia: a pilot study , 2007, Rheumatology International.

[9]  J. Mountz,et al.  Positron emission tomography in patients with fibromyalgia syndrome and healthy controls. , 2004, Arthritis and rheumatism.

[10]  F. Authier,et al.  Aluminum inclusion macrophagic myofasciitis: a recently identified condition. , 2003, Immunology and allergy clinics of North America.

[11]  P. Bartenstein,et al.  Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome , 2003, Journal of neurology, neurosurgery, and psychiatry.

[12]  A. Drzezga,et al.  Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  F. Authier,et al.  Chronic fatigue syndrome in patients with macrophagic myofasciitis. , 2003, Arthritis and rheumatism.

[14]  K. Nas,et al.  Regional cerebral blood flow and cytokines in young females with fibromyalgia. , 2002, Clinical and experimental rheumatology.

[15]  D. Figarella-Branger,et al.  Identical twins with macrophagic myofasciitis: genetic susceptibility and triggering by aluminic vaccine adjuvants? , 2002, Arthritis and rheumatism.

[16]  D. Figarella-Branger,et al.  HLA-DRB1*01 and macrophagic myofasciitis. , 2002 .

[17]  F. Authier,et al.  Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. , 2001, Brain : a journal of neurology.

[18]  D. Lee,et al.  Different uptake of 99mTc-ECD and 99mTc-HMPAO in the same brains: analysis by statistical parametric mapping , 2001, European Journal of Nuclear Medicine.

[19]  K. Pile,et al.  Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. , 2000, Arthritis and rheumatism.

[20]  H. Eichenbaum.  A cortical–hippocampal system for declarative memory , 2000, Nature Reviews Neuroscience.

[21]  Alan C. Evans,et al.  Three-Dimensional MRI Atlas of the Human Cerebellum in Proportional Stereotaxic Space , 1999, NeuroImage.

[22]  G. Sahin,et al.  Determination of aluminum levels in the kidney, liver, and brain of mice treated with aluminum hydroxide , 1994, Biological Trace Element Research.

[23]  R. G. Das,et al.  Aluminium-adjuvanted vaccines transiently increase aluminium levels in murine brain tissue. , 1992, Pharmacology & toxicology.

[24]  L. Negrão,et al.  Macrophagic myofasciitis and vaccination: Consequence or coincidence? , 2014, Rheumatology International.

[25]  H. Wiśniewski,et al.  Histochemical localization of aluminum in the rabbit CNS , 2004, Acta Neuropathologica.

[26]  P. Chérin,et al.  Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Française contre les Myopathies (AFM). , 1998, Lancet.